Real-world cohort study finds half-dose anticoagulation has similar effects on recurrence and bleeding in cancer patients with pulmonary thromboembolism.
Key Points
Extended anticoagulation with half-dose reduces the risk of recurrent PE/DVT without increasing bleeding.
Over a median follow-up of 33.4 months, 20.2% of patients had recurrent PE/DVT despite treatment.
Multivariate analysis shows advanced cancer status and impaired renal function contribute to higher recurrence risk.
Future trials are necessary to refine anticoagulation strategies and identify patient-specific risks in CAPE.